secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001558370-24-013344
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor files BLA for deramiocel in DMD cardiomyopathy; reports ~$85M cash as of Sept 30
--------------------------------------------------------------------------------

- BLA for deramiocel filed Oct 2024 seeking full approval for DMD cardiomyopathy; full submission by year-end 2024.
- HOPE-2/OLE data vs natural history supports BLA; HOPE-3 Cohorts A+B combined as post-approval study, Cohort A unblinding paused.
- StealthX SARS-CoV-2 vaccine selected for Project NextGen; manufacturing ongoing, delivery to NIAID by end-2024.
- Private placement to Nippon Shinyaku: 2.8M shares at $5.36 for ~$15M; ATM sales: 5.5M shares at $9.84 avg for ~$53.9M.
- Preliminary cash balance ~$85M as of Sept 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024013344/0001558370-24-013344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024013344/capr-20241016x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer